Neuphoria Therapeutics Inc.
NEUP | NASDAQ
$3.05
$0.00 (0.00%)
Nov 2, 2026, 12:10 PM ET · Market open
Company Profile
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Spyridon Papapetropoulos | Interim CEO & Executive Director |
| Adrian Hinton | Financial Controller |
| Elizabeth Doolin | Senior Vice President of Clinical Development |
| Julie Kerner | Senior Vice President of Business Operations |
| Rajeev Chandra | Company Secretary |
| Timothy Cunningham | Fractional CFO |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2026 | DEFA14A | Filing |
| Sep 18, 2026 | DEFA14A | Filing |
| Sep 18, 2026 | DEF 14A | Filing |
| Sep 18, 2026 | 10-K | Annual Report |
| Jul 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 24, 2026 | DEFA14A | Filing |
| Jul 24, 2026 | 8-K | Current Report |
| May 26, 2026 | 8-K | Current Report |
| May 15, 2026 | 10-Q | Quarterly Report |
| Feb 17, 2026 | 10-Q | Quarterly Report |
Neuphoria Therapeutics Inc.
| Country | United States |
| IPO Date | Dec 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Spyridon Papapetropoulos |
Contact Details
100 Summit Dr Burlington,
Massachusetts 01803 United States
Stock Details
| Ticker Symbol | NEUP |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001191070 |
| CUSIP Number | 64136E102 |
| ISIN Number | US64136E1029 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove NEUP